UK Markey Cancer Center shared on LinkedIn:
“When standard chemotherapy and immunotherapy fail in advanced small-cell lung cancer, what comes next?
As an NCI-Designated Comprehensive Cancer Center, UK Markey Cancer Center is committed to providing community oncologists and pulmonologists with access to next-generation therapies for their most challenging cases.
We are proud to lead the U.S. Phase 1 trial for ZG006 (Alveltamig), exploring trispecific T-cell engager technology designed to overcome resistance mechanisms in SCLC.
You can also read: WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New Therapeutic Era
